Reaxys: The Shortest Path to Chemistry Data for Early Drug Discovery, Lead Optimization and More


Validating lead candidates that will succeed in preclinical and clinical trials requires efficient access to relevant and accurate data on chemical reactions and bioactivity.



Thanks to powerful search options, expertly curated
databases and tools to support in silico profiling,
Reaxys and Reaxys Medicinal Chemistry provide
direct access to answers for critical decisions
in pharmaceutical R&D, particularly for
lead validation and optimization.



What Our Customers Say

The following customer interviews highlight how chemical data and bioactivity data from Reaxys and Reaxys Medicinal Chemistry provide a distinct advantage in the highly competitive world of pharmaceutical R&D and life sciences.

We very rarely have to go beyond Reaxys and read the source to find what we need.

Dr. Anders Lohse Vice President of Project Management at NCK, discusses the role of high-quality data in his company’s research and how Reaxys supports the optimization of reactions, and more.

Click here to read the full customer interview
(PDF, 796kb)

Pharmaceutical R&D - Dr. Anders Lohse

 

Reaxys makes computational work easier because the chemical and bioactivity data are normalized. We don’t have to perform the normalization ourselves.

Dr. Fabio Tucci, co-founder and COO of Epigen Biosciences, discusses how he and his fellow researchers use chemical data from Reaxys to support their application of advanced hit-to-lead and lead optimization methods, such as in silico profiling.

Click here to read the full Elsevier case study
(PDF, 1.2mb)

Pharmaceutical R&D – Dr. Fabio Tucci

 

Reaxys saves us considerable time. It makes it easier to model the synthesis of new leads and make decisions about which ones to pursue.

Dr. Gary Allred, co-founder, president and CEO of Synthonix, describes how his company uses data on chemical reactions and synthesis routes in the development of highly versatile chemical compounds.

Click here to read the full Elsevier case study
(PDF, 670kb)

Dr. Gary Allred case study - Pharmaceutical R&D | Elsevier

 

Reaxys and Reaxys Medicinal Chemistry] are really well suited to lead identification and validation. The medicinal chemistry data is really useful when we're scoping out the interactions between a target class and similar compounds to our leads.

Dr. Bel Mekonnen, CEO of Hager Biosciences, a start-up focused on the development of lead compounds for unmet medical needs, discusses how drug developer's data needs have changed, and how Reaxys meets them.

Click here to read the full customer interview
(PDF, 450kb)

Pharmaceutical R&D - Dr. Bel Mekonnen

 

Our process research services focus on the development of efficient production processes for selected drug candidates. Reaxys helps our chemists to be more creative and efficient in the lab and thus provide a higher output to our clients.

Dr. Tommi Meulemans, project manager in Mercachem's Organic Synthesis group, focuses on finding innovative, cost-effective and time-efficient ways to deliver on customer requests. Reaxys has the data his team needs.

Click here to read the full customer interview
(PDF, 606kb)

Pharmaceutical R&D - Mercachem

 

Reaxys can quickly lead you to a practical starting point. If you can't find the exact compound, you just search for similar sequences of reactions to get to the target compounds.

Takahashi Nakai, a medicinal chemist at Ironwood Pharmaceuticals, describes how Reaxys supports him with a multitude of tasks: SAR analyses, target identification, synthesis route planning and compound characterization.

Click here to read the full customer interview
(PDF, 591kb)

Pharmaceutical R&D - Ironwood

Reaxys Fact Sheet

Reaxys provides powerful search options to give researchers total control of their search, ensuring only the most relevant answers to their chemistry questions.

Download the Reaxys Fact Sheet (PDF, 1.7mb)

Reaxys Medicinal Chemistry Fact Sheet

Reaxys Medicinal Chemistry empowers hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.

Download the Reaxys Medicinal Chemistry Fact Sheet (PDF, 1.2mb)


Real Stories. Real Science. Real Time.

Visit the Hive and meet the biotech and pharma start-ups using Elsevier R&D solutions to solve early-stage drug discovery and development. Watch videos, read real-world case studies and learn how innovation starts with rapid results and access to crucial research in reducing costly late stage failures and mitigating risk.

Learn more about the Hive



Industry Insights for Pharmaceutical R&D Professionals


Enabling Data-Based Decision-Making for Successful Drug Development





Enabling Data-Based Decision-Making for Successful Drug Development

Ensuring that data available to researchers is both high quality and easily discoverable is of paramount importance. Discover how Reaxys Medicinal Chemistry delivers high-quality, easily discoverable data.

Read more (PDF, 765kb)


Big Data Demands Big Innovation

The narrow scope of target-oriented drug creation operates within a fraction of the space that is relevant to the actual use of drugs. What innovative new approaches can overcome this disconnect?

Read more


Big Data Demands Big Innovation

10 shortlisted candidates from the 2016 Reaxys Prize announced | Elsevier

10 shortlisted candidates from the 2016 Reaxys Prize announced

The ten shortlisted candidates will give oral presentations at the Reaxys Prize Symposium on 22-23 September at the New Scientist Live in London, UK. Three winners will be chosen from the finalists’ presentations and announced at the Symposium dinner.

All 45 original finalists from this year’s Prize have been invited to attend the Symposium and present their work during a poster session.

Register your interest for next year's Reaxys PhD Prize.